Compare CHYM & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHYM | SRRK |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | 1519 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.6B |
| IPO Year | N/A | 2018 |
| Metric | CHYM | SRRK |
|---|---|---|
| Price | $20.96 | $56.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 13 |
| Target Price | $31.94 | ★ $56.17 |
| AVG Volume (30 Days) | ★ 5.4M | 1.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.65 | N/A |
| Revenue Next Year | $19.12 | $534.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.88 | $27.07 |
| 52 Week High | $38.67 | $57.80 |
| Indicator | CHYM | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 61.69 | 67.10 |
| Support Level | $16.64 | $44.08 |
| Resistance Level | $21.68 | N/A |
| Average True Range (ATR) | 1.23 | 2.39 |
| MACD | 0.41 | 0.60 |
| Stochastic Oscillator | 84.04 | 83.97 |
Chime Financial Inc is a financial technology company that provides digital banking services through its proprietary technology platform in partnership with third-party banks. The company offers various financial products and services designed to meet members' financial needs, including spending accounts, liquidity solutions, credit-building tools, savings products, and community-focused financial services.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.